442 related articles for article (PubMed ID: 25083058)
21. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype.
Belmonte L; Beutheu Youmba S; Bertiaux-Vandaële N; Antonietti M; Lecleire S; Zalar A; Gourcerol G; Leroi AM; Déchelotte P; Coëffier M; Ducrotté P
PLoS One; 2012; 7(8):e42777. PubMed ID: 23028414
[TBL] [Abstract][Full Text] [Related]
22. Soluble mediators in plasma from irritable bowel syndrome patients excite rat submucosal neurons.
O'Malley D; Buckley MM; McKernan DP; Quigley EM; Cryan JF; Dinan TG
Brain Behav Immun; 2015 Feb; 44():57-67. PubMed ID: 25150006
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in the pathophysiology of irritable bowel syndrome.
El-Salhy M
World J Gastroenterol; 2015 Jul; 21(25):7621-36. PubMed ID: 26167065
[TBL] [Abstract][Full Text] [Related]
24. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation.
Fukudo S
J Gastroenterol; 2007 Jan; 42 Suppl 17():48-51. PubMed ID: 17238026
[TBL] [Abstract][Full Text] [Related]
25. Close association between intestinal microbiota and irritable bowel syndrome.
Fan WT; Ding C; Xu NN; Zong S; Ma P; Gu B
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2303-2317. PubMed ID: 28785822
[TBL] [Abstract][Full Text] [Related]
26. Is irritable bowel syndrome an organic disorder?
El-Salhy M; Gundersen D; Gilja OH; Hatlebakk JG; Hausken T
World J Gastroenterol; 2014 Jan; 20(2):384-400. PubMed ID: 24574708
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome.
Salvo-Romero E; Martínez C; Lobo B; Rodiño-Janeiro BK; Pigrau M; Sánchez-Chardi AD; González-Castro AM; Fortea M; Pardo-Camacho C; Nieto A; Expósito E; Guagnozzi D; Rodríguez-Urrutia A; de Torres I; Farré R; Azpiroz F; Alonso-Cotoner C; Santos J; Vicario M
Sci Rep; 2020 Nov; 10(1):20706. PubMed ID: 33244004
[TBL] [Abstract][Full Text] [Related]
28. Aspects of the non-pharmacological treatment of irritable bowel syndrome.
Eriksson EM; Andrén KI; Kurlberg GK; Eriksson HT
World J Gastroenterol; 2015 Oct; 21(40):11439-49. PubMed ID: 26523108
[TBL] [Abstract][Full Text] [Related]
29. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome.
Chen J; Zhang Y; Deng Z
BMC Gastroenterol; 2012 Jul; 12():91. PubMed ID: 22816602
[TBL] [Abstract][Full Text] [Related]
30. Glioplasticity in irritable bowel syndrome.
Lilli NL; Quénéhervé L; Haddara S; Brochard C; Aubert P; Rolli-Derkinderen M; Durand T; Naveilhan P; Hardouin JB; De Giorgio R; Barbara G; Bruley des Varannes S; Coron E; Neunlist M
Neurogastroenterol Motil; 2018 Apr; 30(4):e13232. PubMed ID: 29027719
[TBL] [Abstract][Full Text] [Related]
31. Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome.
Santos J; Alonso C; Vicario M; Ramos L; Lobo B; Malagelada JR
Curr Mol Med; 2008 Jun; 8(4):258-73. PubMed ID: 18537634
[TBL] [Abstract][Full Text] [Related]
32. CRF1 receptors as a therapeutic target for irritable bowel syndrome.
Martinez V; Taché Y
Curr Pharm Des; 2006; 12(31):4071-88. PubMed ID: 17100612
[TBL] [Abstract][Full Text] [Related]
33. Gene, environment, and brain-gut interactions in irritable bowel syndrome.
Fukudo S; Kanazawa M
J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():110-5. PubMed ID: 21443722
[TBL] [Abstract][Full Text] [Related]
34. Stress and visceral pain: focusing on irritable bowel syndrome.
Fukudo S
Pain; 2013 Dec; 154 Suppl 1():S63-S70. PubMed ID: 24021863
[TBL] [Abstract][Full Text] [Related]
35. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
[TBL] [Abstract][Full Text] [Related]
36. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
[TBL] [Abstract][Full Text] [Related]
37. Review article: intestinal serotonin signalling in irritable bowel syndrome.
Mawe GM; Coates MD; Moses PL
Aliment Pharmacol Ther; 2006 Apr; 23(8):1067-76. PubMed ID: 16611266
[TBL] [Abstract][Full Text] [Related]
38. A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China.
Liu J; Hou X
J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():88-93. PubMed ID: 21443718
[TBL] [Abstract][Full Text] [Related]
39. Irritable Bowel Syndrome and Stress-Related Psychiatric Co-morbidities: Focus on Early Life Stress.
O'Mahony SM; Clarke G; Dinan TG; Cryan JF
Handb Exp Pharmacol; 2017; 239():219-246. PubMed ID: 28233180
[TBL] [Abstract][Full Text] [Related]
40. Cognitive behavioral therapy for irritable bowel syndrome: the effects on state and trait anxiety and the autonomic nervous system during induced rectal distensions - An uncontrolled trial.
Edebol-Carlman H; Schrooten M; Ljótsson B; Boersma K; Linton S; Brummer RJ
Scand J Pain; 2018 Jan; 18(1):81-91. PubMed ID: 29794287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
